Long-term virological outcome in children on antiretroviral therapy in the UK and Ireland

Duong, Trinh and Judd, Ali and Collins, Intira Jeannie and Doerholt, Katja and Lyall, Hermione and Foster, Caroline and Butler, Karina and Tookey, Pat and Shingadia, Delane and Menson, Esse and Dunn, David T. and Gibb, Di M. and Smyth, Alan R. (2014) Long-term virological outcome in children on antiretroviral therapy in the UK and Ireland. AIDS, 28 (16). pp. 2395-2405. ISSN 1473-5571

[img]
Preview
PDF (Long term virological outcome) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
Available under Licence Creative Commons Attribution Non-commercial No Derivatives.
Download (522kB) | Preview

Abstract

Objective: To assess factors at the start of antiretroviral therapy (ART) associated with long-term virological response in children.

Design: Multicentre national cohort.

Methods: Factors associated with viral load below 400 copies/ml by 12 months and virologic failure among children starting 3/4-drug ART in the UK/Irish Collaborative HIV Paediatric Study were assessed using Poisson models.

Results: Nine hundred and ninety-seven children started ART at a median age of 7.7 years (inter-quartile range 2.9–11.7), 251 (25%) below 3 years: 411 (41%) with efavirenz and two nucleoside reverse transcriptase inhibitors (EFVþ2NRTIs), 264 (26%) with nevirapine and two NRTIs (NVPþ2NRTIs), 119 (12%; 106 NVP, 13 EFV) with non-nucleoside reverse transcriptase inhibitor and three NRTIs (NNRTIþ3NRTIs), and 203 (20%) with boosted protease inhibitor-based regimens. Median follow-up after ART initiation was 5.7 (3.0–8.8) years. Viral load was less than 400 copies/ml by 12 months in 92% [95% confidence interval (CI) 91–94%] of the children. Time to suppression was similar across regimens (P¼0.10), but faster over calendar time, with older age and lower baseline viral load. Three hundred and thirtynine (34%) children experienced virological failure. Although progression to failure varied by regimen (P<0.001) and was fastest for NVPþ2NRTIs regimens, risk after 2 years on therapy was similar for EFVþ2NRTIs and NVPþ2NRTIs, and lowest for NNRTIþ3NRTIs regimens (P-interaction¼0.03). Older age, earlier calendar periods and maternal ART exposure were associated with increased failure risk. Early treatment discontinuation for toxicity occurred more frequently for NVP-based regimens, but 5-year cumulative incidence was similar: 6.1% (95% CI 3.9–8.9%) NVP, 8.3% (95% CI 5.6–11.6) EFV, and 9.8% (95% CI 5.7–15.3%) protease inhibitor-based regimens (P¼0.48).

Conclusion: Viral load suppression by 12 months was high with all regimens. NVPþ3NRTIs regimens were particularly efficacious in the longer term and may be a good alternative to protease inhibitor-based ART in young children.

Item Type: Article
Keywords: antiretroviral therapy, children, HIV, UK/Ireland, virological outcome
Schools/Departments: University of Nottingham UK Campus > Faculty of Medicine and Health Sciences > School of Medicine > Division of Child Health, Obstetrics and Gynaecology
Identification Number: https://doi.org/10.1097/QAD.0000000000000438
Depositing User: Smyth, Prof Alan
Date Deposited: 15 Feb 2016 10:30
Last Modified: 14 Sep 2016 14:51
URI: http://eprints.nottingham.ac.uk/id/eprint/31690

Actions (Archive Staff Only)

Edit View Edit View